GlassScriptPhysician profile
Rouzbeh Fateh
NPI 1215270533
$1,089.75
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $11.16 · 2022: $170.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $349.24 | 2019 | |
| Akcea Therapeutics, INC. | $282.82 | 2019-2020 | |
| Allergan, INC. | $217.45 | 2019 | |
| Abbvie INC. | $148.32 | 2022 | |
| Ucb, INC. | $43.75 | 2019 | |
| Emd Serono, INC. | $26.79 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.38 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rouzbeh Fateh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.